Skip to main content
    Curevo Weight
    Menu closed

    RetatrutideTriple agonistGLP-1

    Retatrutide - triple-agonist weight loss: results and outlook

    Retatrutide is a new triple agonist (GLP-1, GIP, glucagon) showing promising weight-loss results, but it is not yet approved.

    Retatrutide - triple-agonist weight loss: results and outlook
    Author
    Dr Dorel Lehrer, Licensed Physician
    Reading time
    10 min
    Content
    Rx education
    Last updated

    Quick answer

    Retatrutide targets three receptors and has shown strong weight-loss outcomes in trials. It remains investigational in many markets.

    Retatrutide is an investigational medication designed to target three metabolic pathways and may deliver substantial weight loss.

    What makes it different

    By activating GLP-1, GIP, and glucagon receptors, retatrutide aims to improve appetite regulation and energy balance.

    Current status

    The medication is still under clinical investigation and is not yet broadly approved.

    Medical information, not medicine advertising

    This article is educational and does not replace individual care. Which medicine may be relevant is decided by a licensed doctor after medical assessment. Prescription issuing is included only when a doctor decides it is medically appropriate.

    DD

    Dr Dorel Lehrer

    Licensed Physician

    Medical Director at Viktenheten
    Experienced in medical weight management

    This article is medical information written by Dr Dorel Lehrer, Licensed Physician. Any treatment follows an individual assessment by a licensed doctor.

    Related Articles

    View all articles

    Discover more